Physician profile
Thomas O'Brien
NPI 1053419879
$767.02
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $322 · 2020: $264 · 2021: $154 · 2022: $26.89.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $361.16 | 2019-2021 | |
| Therapeuticsmd, INC. | $118.35 | 2019-2022 | |
| Daiichi Sankyo INC. | $58.44 | 2020-2021 | |
| Smith+Nephew, INC. | $43.99 | 2019-2020 | |
| Boston Scientific Corporation | $41.38 | 2019 | |
| Merck Sharp & Dohme LLC | $35.89 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.59 | 2019-2020 | |
| Exeltis, USA INC. | $18.77 | 2021 | |
| Pfizer INC. | $15.38 | 2019 | |
| Amag Pharmaceuticals, INC. | $13.80 | 2019 | |
| Medicem INC. | $13.19 | 2021 | |
| Allergan, INC. | $13.08 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas O'Brien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.